(b) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of the fiscal years 
2013 through 2017. 
SEC. 5. SURVEILLANCE CAPACITY BUILDING. 
(a) PROGRAM AUTHORIZED.—The Director of the 
Centers for Disease Control and Prevention shall award 
grants or cooperative agreements to State, local, or tribal 
governments, or the National Poison Data System, work-
ing in conjunction with the State, local, or tribal govern-
ments, to improve fatal and nonfatal drug overdose sur-
veillance and reporting capabilities, including the fol-
lowing: 
(1) Implementing or enhancing the capacity of 
a coroner or medical examiner’s office to conduct 
toxicological screenings where drug overdose is the 
suspected cause of death. 
(2) Providing training to improve identification 
of drug overdose as the cause of death by coroners 
and medical examiners. 
(3) Establishing, in cooperation with the Na-
tional Poison Data System, coroners, and medical 
examiners, a comprehensive national program for 
surveillance of, and reporting to an electronic data-
base on, drug overdose deaths in the United States. 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
(4) Establishing, in cooperation with the Na-
tional Poison Data System, a comprehensive na-
tional program for surveillance of, and reporting to 
an electronic database on, fatal and nonfatal drug 
overdose occurrences, including epidemiological and 
toxicologic analysis and trends. 
(b) APPLICATION.— 
(1) IN GENERAL.—A State, local, or tribal gov-
ernment or the National Poison Data System desir-
ing a grant or cooperative agreement under this sec-
tion shall submit to the Director an application at 
such time, in such manner, and containing such in-
formation as the Director may require. 
(2) CONTENTS.—The application described in 
paragraph (1) shall include— 
(A) a description of the activities to be 
funded through the grant or cooperative agree-
ment; and 
(B) a demonstration that the State, local, 
or tribal government or the National Poison 
Data System has the capacity to carry out such 
activities. 
(c) REPORT.—As a condition on receipt of a grant 
or cooperative agreement under this section, a State, local, 
or tribal government or the National Poison Data System 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
shall agree to prepare and submit, not later than 90 days 
after the end of the grant or cooperative agreement period, 
a report to the Director describing the results of the activi-
ties supported through the grant or cooperative agree-
ment. 
(d) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of the fiscal years 
2013 through 2017. 
SEC. 6. REDUCING OVERDOSE DEATHS. 
(a) IN GENERAL.—Not later than 180 days after the 
date of the enactment of this Act, the Secretary of Health 
and Human Services shall develop a plan in consultation 
with a task force comprised of stakeholders to reduce the 
number of deaths occurring from overdoses of drugs and 
shall submit the plan to Congress. The plan shall in-
clude— 
(1) an identification of the barriers to obtaining 
accurate data regarding the number of deaths occur-
ring from overdoses of drugs; 
(2) an identification of the barriers to imple-
menting more effective overdose prevention strate-
gies and programs; 
(3) an examination of overdose prevention best 
practices; 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
(4) a plan for implementation of a public health 
campaign to educate physicians and the public about 
overdose prevention and naloxone prescription; 
(5) recommendations for improving and ex-
panding overdose prevention programming; and 
(6) recommendations for such legislative or ad-
ministrative action as the Director considers appro-
priate. 
(b) DEFINITION.—In this section, the term ‘‘stake-
holder’’ means any individual directly impacted by drug 
overdose, any direct service provider who engages individ-
uals at risk of a drug overdose, any drug overdose preven-
tion advocate, the National Institute on Drug Abuse, the 
Center for Substance Abuse Treatment, the Centers for 
Disease Control and Prevention, the Food and Drug Ad-
ministration, the American Association of Poison Control 
Centers, and any other individual or entity with drug over-
dose expertise. 
SEC. 7. OVERDOSE PREVENTION RESEARCH. 
(a) OVERDOSE RESEARCH.—The Director of the Na-
tional Institute on Drug Abuse shall prioritize and conduct 
or support research on drug overdose and overdose preven-
tion. The primary aims of this research shall include— 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00012
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS
(1) examinations of circumstances that contrib-
uted to drug overdose and identification of drugs as-
sociated with fatal overdose; 
(2) evaluations of existing overdose prevention 
program intervention methods; and 
(3) pilot programs or research trials on new 
overdose prevention strategies or programs that have 
not been studied in the United States. 
(b) DOSAGE FORMS OF NALOXONE.—The Director 
of the National Institute on Drug Abuse shall support re-
search on the development of dosage forms of naloxone 
specifically intended to be used by lay persons or first re-
sponders for the prehospital treatment of unintentional 
drug overdose. 
(c) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to carry out this section 
such sums as may be necessary for each of the fiscal years 
2013 through 2017. 
SEC. 8. DEFINITIONS. 
In this Act: 
(1) DIRECTOR.—Unless otherwise specified, the 
term ‘‘Director’’ means the Director of the Centers 
for Disease Control and Prevention. 
(2) DRUG.—The term ‘‘drug’’— 
VerDate Mar 15 2010 
02:22 Aug 15, 2012
Jkt 019200
PO 00000
Frm 00013
Fmt 6652
Sfmt 6201
E:\BILLS\H6311.IH
H6311
jbell on DSK7SPTVN1PROD with BILLS